Files
Abstract
The involvement of the Janus Kinase (JAK) and Signal Transducer and Activator of Transcription (STAT) signaling pathway in various human autoimmune diseases and hematopoietic neoplasms is well-studied, and JAK/STAT inhibitors have been developed to treat these diseases. However, studies investigating the role of the JAK/STAT pathway in canine tumors are lacking. The present study evaluated inhibitory effects of four different JAK inhibitors (AZD1480, oclacitinib, INCB39110: itacitinib, CP-690550: tofacitinib) on cell growth and survival of canine B- and T-cell lymphoma cell lines (OSW, 17-71, Ema, CLBL-1). AZD1480 showed significant dose-dependent inhibitory effects on all cell lines, inducing apoptosis and disruption of cell cycle while oclacitinib showed weaker inhibitory effects at high concentrations. INCB39110 (itacitinib) and CP-690550 (tofacitinib) induced no significant inhibitory effects. These in vitro findings suggest that inhibition of JAK2 signaling could be a potential alternative treatment option for canine lymphomas, and further investigations are warranted.